Galderma
CompanySwitzerlandFounded 1981
Galderma develops 3 assets, the furthest in phase 3 (Nemluvio in atopic dermatitis). Mostly antibody and other acting on inflammation, IL31RA and CD44; based in Switzerland, founded in 1981.
- 3
- Assets
- Furthest
- Phase 3
- 9
- Trials
- 0
- Signals
Pipeline
3Monoclonal antibody targeting IL-31 receptor alpha to inhibit itching and inflammation.
Phase 3, Antibody, Inflammation, IL31RA, atopic dermatitis
Dermal filler providing structural support and tissue augmentation
Phase 3, Other, CD44, aesthetic, facial aesthetic treatment
Hyaluronic acid dermal filler providing volume restoration and aesthetic correction of facial tissue.
Phase 3, Device, aesthetic, facial aesthetic treatment
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms3
- Trials11
- Similar companies6
Updated 9 Oct 2026 · 28 sources